Stryker Corporation

New York Stock Exchange
Back to all articles
Slightly Bullish +25

BTIG Research Issues Pessimistic Forecast for Stryker (NYSE:SYK) Stock ...

📉 BTIG Research reduced its Stryker price target to $358.00 from $371.00 while maintaining a 'buy' rating.

📊 Wells Fargo and Canaccord Genuity also lowered their price targets, whereas Goldman Sachs issued a neutral rating.

💰 The company beat Q2 earnings estimates with $3.69 EPS and revenue of $6.59 billion up 9.4% year-over-year.

📈 Stryker provided FY 2026 guidance between $14.95 and $15.10 per share, slightly below the average analyst forecast of $15.01.

💸 Director Ronda E. Stryker sold 310,000 shares for $96.8 million, representing a 13.87% reduction in her holdings.

📉 Vice President Robert S. Fletcher sold 4,544 shares for $1.4 million under a Rule 10b5-1 trading plan.

🏦 Wellington Management Group increased its position by 22.6%, adding over 1.19 million shares to its portfolio.

🇳🇴 Norges Bank established a new position in Stryker valued at approximately $1.82 billion during the fourth quarter.

📊 Institutional ownership remains high at 77.09% with Vanguard and State Street also increasing their stakes.

🏥 Stryker operates across orthopedics, surgical equipment, neurotechnology, and patient-handling solutions globally.

Bullish Signals
  • Stryker reported earnings per share of $3.69, beating analyst consensus estimates of $3.49 by $0.20.
  • Revenue grew 9.4% year-over-year to reach $6.59 billion, exceeding the expected $6.58 billion.
  • The company maintains a healthy net margin of 14.43% and a return on equity of 24.06%.
  • Wellington Management Group significantly increased its stake by 22.6%, adding over 1.19 million shares.
  • Norges Bank initiated a new position valued at $1.82 billion, indicating strong institutional interest.
  • Vanguard and State Street both raised their holdings, with Vanguard increasing by 0.4% and State Street by 2.1%.
Risk Factors
  • BTIG Research lowered its price target to $358.00 from $371.00, citing a reduced valuation outlook.
  • Wells Fargo & Company dropped its target price from $456.00 to $418.00 despite maintaining an overweight rating.
  • Canaccord Genuity decreased its price objective from $435.00 to $400.00 in a recent report.
  • Director Ronda E. Stryker sold 310,000 shares for $96.8 million, reducing her ownership by 13.87%.
  • Vice President Robert S. Fletcher sold 4,544 shares for $1.4 million, decreasing his ownership by 30.04%.
Full Analysis
BTIG Research lowered its price target for Stryker (NYSE:SYK) from $371.00 to $358.00, though the firm maintains a 'buy' rating indicating potential upside of 9.68%. This move aligns with recent analyst actions where Wells Fargo and Canaccord Genuity also reduced their price targets, while Goldman Sachs issued a neutral rating and Robert W. Baird set a higher objective at $385.00. The company reported strong quarterly financial results on July 30th, posting $3.69 in earnings per share against a consensus of $3.49. Revenue reached $6.59 billion, representing a 9.4% year-over-year increase, with net margins at 14.43% and return on equity at 24.06%. Management provided fiscal 2026 guidance ranging between $14.95 and $15.10 per share. Insider trading activity saw significant selling from Director Ronda E. Stryker, who sold 310,000 shares for approximately $96.8 million, reducing her ownership by nearly 14%. Vice President Robert S. Fletcher also sold shares under a pre-arranged plan. Conversely, major institutional investors like Wellington Management Group increased their stakes significantly, with Norges Bank initiating a new position valued at over $1.8 billion.